Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future
- 24 December 2014
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Neurotherapeutics
- Vol. 15 (1), 83-105
- https://doi.org/10.1586/14737175.2015.995637
Abstract
Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Consequently, therapeutic concepts and targets have been increasingly focused on early-stage illness before the onset of dementia; and distinct classes of compounds are now being tested in clinical trials. At present, there is a growing consensus that therapeutic progress in AD delaying disease progression would significantly decrease the expanding global burden. The evolving hypothesis- and evidence-based generation of new diagnostic research criteria for early-stage AD has positively impacted the development of clinical trial designs and the characterization of earlier and more specific target populations for trials in prodromal as well as in pre- and asymptomatic at-risk stages of AD.Keywords
This publication has 128 references indexed in Scilit:
- MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy studyBMJ Open, 2013
- Preclinical Alzheimer disease—the challenges aheadNature Reviews Neurology, 2012
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseThe New England Journal of Medicine, 2012
- The projected effect of risk factor reduction on Alzheimer's disease prevalenceThe Lancet Neurology, 2011
- Passive Immunization with Anti-Tau Antibodies in Two Transgenic ModelsJournal of Biological Chemistry, 2011
- Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementiaTrends in Neurosciences, 2011
- Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm ShiftNeuron, 2011
- Nature versus Nurture: Death of a Dogma, and the Road AheadNeuron, 2010
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991